Brief Report|Articles in Press

Brief Report: Canadian Cancer Trials Group IND.227: A Phase II randomized study of pembrolizumab in patients with advanced malignant pleural mesothelioma (NCT02784171).

Published:February 23, 2023DOI:
      This paper is only available as a PDF. To read, Please Download here.


      Immune checkpoint inhibitors have activity in mesothelioma. IND.227 was a phase II trial (120 patients planned) comparing progression free survival (PFS) of standard platinum pemetrexed (CP) versus CP/pembrolizumab (CP/pembro) versus pembrolizumab (pembro) . Accrual to pembro arm was discontinued based on interim analysis (IA - 16 week disease control rate (DCR)). CP/pembro was tolerable, with PFS similar between arms and median survival (OS) and overall response rate (RR) higher than CP alone (19.8 months [95% CI 8.4– 41.36] vs 8.9 months [95% CI 5.3 – 12.8] and 47 % [95 % CI 24-71%] vs 19% [95% CI 5--42%], respectively).
      The subsequent phase III trial has completed accrual; results are expected in 2023.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Thoracic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect